European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Eur Heart J. 2017 Aug 1;38(29):2245-2255. doi: 10.1093/eurheartj/ehw480.
No abstract available

MeSH terms

  • Cardiology / organization & administration
  • Cardiovascular Agents* / adverse effects
  • Cardiovascular Agents* / therapeutic use
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / mortality
  • Cardiovascular Diseases* / prevention & control
  • Cholesterol / blood
  • Consensus
  • Enzyme Inhibitors* / adverse effects
  • Enzyme Inhibitors* / therapeutic use
  • Humans
  • Hyperlipoproteinemia Type II* / drug therapy
  • Hyperlipoproteinemia Type II* / mortality
  • Hyperlipoproteinemia Type II* / prevention & control
  • PCSK9 Inhibitors*
  • Practice Guidelines as Topic
  • Risk Factors

Substances

  • Cardiovascular Agents
  • Enzyme Inhibitors
  • PCSK9 Inhibitors
  • Cholesterol
  • PCSK9 protein, human